Table 2.

Structural changes at Month 12.*

VariablesTofacitinib 5 mg BID, N = 98Tofacitinib 10 mg BID, N = 99ADA 40 mg SC Q2W, N = 95
mTSS nonprogression (change ≤ 0.5), n (%)94 (95.9)94 (94.9)93 (97.9)
mTSS nonprogression (change ≤ 0), n (%)89 (90.8)92 (92.9)91 (95.8)
mTSS nonprogression (SDC, change ≤ 0.66), n (%)94 (95.9)94 (94.9)93 (97.9)
LSM change from BL mTSS (SE)0.01 (0.067)−0.01 (0.067)−0.07 (0.069)
LSM change from BL erosion score (SE)0.02 (0.059)−0.00 (0.059)−0.06 (0.062)
LSM change from BL JSN score (SE)−0.01 (0.021)−0.01 (0.021)−0.01 (0.021)
  • * Linear extrapolation applied at Month 12. No. patients with imputed values at Month 12 by linear extrapolation: tofacitinib 5 mg BID (n = 3); tofacitinib 10 mg BID (n = 4); adalimumab (n = 3). LSM were based on an ANCOVA model. ADA: adalimumab; BID: twice daily; BL: baseline; JSN: joint space narrowing; LSM: least squares mean; mTSS: modified Total Sharp Score; N: no. patients with data available at Month 12 after linear extrapolation; n: no. patients with nonprogression; Q2W: once every 2 weeks; SC: subcutaneous; SDC: smallest detectable change; SE: standard error.